Document Detail

Immunomodulating therapy: new treatment modality in congestive heart failure.
MedLine Citation:
PMID:  12671336     Owner:  NLM     Status:  MEDLINE    
Accumulating evidence indicates that inflammatory cytokines play a pathogenic role in congestive heart failure (CHF) by influencing heart contractility, inducing hypertrophy, and promoting apoptosis or fibrosis, contributing to the continuous myocardial remodeling process. Traditional cardiovascular drugs seem to have little influence on the overall cytokine network, and immunomodulatory therapy has emerged as a possible new treatment modality in CHF. Several animal studies have suggested that modulation of inflammatory cytokines may improve cardiac performance. The authors have recently demonstrated that intravenous immunoglobulin enhances the left ventricular ejection fraction in CHF patients, and that this is significantly correlated with anti-inflammatory effects of such therapy. While intravenous immunoglobulin is not necessarily the drug of choice, this study suggests a potential role for immunomodulatory therapy in CHF in addition to optimal cardiovascular treatment regimens. Further research will more precisely identify the most important actors in the immunopathogenesis of CHF and contribute to the development of more specific immunomodulating agents for this disorder.
Pål Aukrust; Jan Kristian Damås; Lars Gullestad
Related Documents :
16036026 - Inhibition of raas--when is it too much?
18221596 - Update on inotropic therapy in the management of acute heart failure.
25154776 - Clopidogrel with aspirin versus aspirin alone in prevention of stroke following transie...
22385756 - Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hyp...
3630776 - Predictive value of prodromal symptoms in myocardial infarction.
24449356 - Mri demonstrates a decrease in myocardial infarct healing and increase in compensatory ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Congestive heart failure (Greenwich, Conn.)     Volume:  9     ISSN:  1527-5299     ISO Abbreviation:  Congest Heart Fail     Publication Date:    2003 Mar-Apr
Date Detail:
Created Date:  2003-04-02     Completed Date:  2003-06-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9714174     Medline TA:  Congest Heart Fail     Country:  United States    
Other Details:
Languages:  eng     Pagination:  64-9     Citation Subset:  IM    
Copyright Information:
Copyright 2003 CHF, Inc.
Section of Clinical Immunology and Infectious Diseases, Medical Department, Rikshospitalet, Sognsvannsveien 20, 0027 Oslo, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / therapeutic use*
Cytokines / diagnostic use,  physiology,  therapeutic use
Evidence-Based Medicine
Heart Failure / diagnosis,  drug therapy,  immunology
Inflammation Mediators / diagnostic use,  immunology,  therapeutic use
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Cytokines; 0/Inflammation Mediators

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Scleroderma renal crisis.
Next Document:  Neurohormonal abnormalities in heart failure: impact of exercise training.